J Interv Cardiol
-
Publication Venue For
- Editorial: Navigating the rough seas of anemia; caught between the devil and the deep blue sea.. 30:500-501. 2017
- Editorial: Radial to Coronary: Ideal Catheter for the Ideal Approach.. 30:43-45. 2017
- Thrombin-Induced Platelet-Fibrin Clot Strength Identified by Thrombelastography: A Novel Prothrombotic Marker of Coronary Artery Stent Restenosis.. 29:168-178. 2016
- Platelet Function Testing Before CABG is Recommended in the Guidelines: But Do We Have Enough Evidence?. 28:233-235. 2015
- Improving integrated care in low- and middle-income countries: the final STEMI frontier?. 27:167-170. 2014
- The current use of Impella 2.5 in acute myocardial infarction complicated by cardiogenic shock: results from the USpella Registry.. 27:1-11. 2014
- Would tirofiban have been shown non-inferior to abciximab had the TENACITY trial not been terminated for financial reasons?. 26:123-130. 2013
- Sustained low clinical event rates in real-world patients receiving everolimus-eluting coronary stent system from a large, prospective, condition of approval study: 2-year clinical outcomes from the XIENCE V USA Study.. 25:565-575. 2012
- Low-dose versus high-dose aspirin after percutaneous coronary intervention: analysis from the guthrie health off-label StenT (GHOST) registry.. 24:307-314. 2011
- Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction.. 22:378-384. 2009
- The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome.. 21 Suppl 1:S10-S17. 2008
- Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion.. 21:283-299. 2008